Product Images Lisdexamfetamine Dimesylate

This is a description for Lisdexamfetamine Dimesylate Chewable Tablets. These tablets contain Lisdexamfetamine dimesylate 10 mg (equivalent to 5.8 mg lisdexamfetamine) and come in a pack of 100 chewable tablets. Instructions state to chew the tablets completely before swallowing and not to swallow them whole. A separate Medication Guide should be dispensed to each patient. Dosage information can be found in the package insert. The tablets should be stored at 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F). The tablets should be dispensed in a tight, light-resistant container with a child-resistant closure. Manufacturing information is provided as Granules Pharmaceuticals Inc., Chantilly, VA 20151. The revision date of the information is 11/2024.*

This is information about a medication called Lisdexamfetamine Dimesylate Chewable Tablets H 20 mg C. The tablets should be chewed completely before swallowing and should not be swallowed whole. The pharmacist should dispense a Medication Guide to each patient. Each chewable tablet contains Lisdexamfetamine dimesylate 20 mg. The dosage information can be found in the package insert. The tablets should be stored at 20° to 25°C (68° to 77°F). The medication should be dispensed in a tight, light-resistant container with a child-resistant closure. The medication is manufactured by Granules Pharmaceuticals Inc. in Chantilly, VA.*

This is a description of a medication called Lisdexamfetamine Dimesylate Chewable Tablets. Each chewable tablet contains 30 mg of Lisdexamfetamine dimesylate (equivalent to 17.3 mg lisdexamfetamine). It is recommended to chew the tablets completely before swallowing and not to swallow them whole. The medication guide should be dispensed separately to each patient by the pharmacist. Dosage information can be found in the package insert. The tablets should be stored at 20° to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). It should be dispensed in a tight, light-resistant container with a child-resistant closure. The medication is manufactured by Granules Pharmaceuticals Inc. in Chantilly, VA.*

This is a description for chewable tablets of Lisdexamfetamine Dimesylate with a strength of 40 mg. The tablets should be chewed thoroughly before swallowing. Each tablet contains 40 mg of Lisdexamfetamine dimesylate (equivalent to 23.1 mg of lisdexamfetamine). The pharmacist should dispense the medication guide to each patient. Dosage information can be found in the package insert. The tablets should be stored at 20° to 25°C (68° to 77°F) with excursions permitted to 15°-30°C (59°-86°F). The medication should be dispensed in a tight, light-resistant container with a child-resistant closure. The tablets are manufactured by Granules Pharmaceuticals Inc. in Chantilly, VA.*

This is a prescription medication for Lisdexamfetamine Dimesylate Chewable Tablets. Each tablet contains 50 mg of Lisdexamfetamine dimesylate (equivalent to 28.9 mg lisdexamfetamine). The tablets should be chewed completely before swallowing. It should be dispensed with the Medication Guide provided to each patient. Store the medication at 20° to 25°C (68° to 77°F) with excursions permitted to 15°to 30°C (59° to 86°F). Dispense in a tight, light-resistant container with a child-resistant closure. For dosage information and further details, refer to the package insert. The medication is manufactured by Granules Pharmaceuticals Inc.*

This is a medication label for Lisdexamfetamine Dimesylate Chewable Tablets in 60 mg strength. It is meant for prescription use only and the tablets should be chewed completely before swallowing. The package insert should be consulted for dosage information. The tablets should be stored at a temperature between 20° to 25°C (68° to 77°F). Dispensing should be done in a tight, light-resistant container with a child-resistant closure. More information can be found in the Medication Guide provided. The medication is manufactured by Granules Pharmaceuticals Inc. in Chantilly, VA 20151.*

This text provides information on special populations based on gender (male/female) and age categories: 65-74 years and >=75 years. It also includes different levels of renal impairment (mild, moderate, end-stage renal disease), as well as pharmacokinetics data such as fold change, 90% confidence intervals, and changes relative to reference.*

This document appears to discuss changes in pharmacokinetic parameters (PK) such as AUC (area under the curve) of Guanfacine, Venlafaxine, and Omeprazole. It also involves calculating fold changes and 90% confidence intervals with different time points mentioned like 05, 10, and 15. Furthermore, the text suggests analyzing the changes relative to a reference point (possibly 0.0).*

This text appears to show the interacting drug's impact on the pharmacokinetics (PK) of various substances, including Guanfacine, Venlafaxine, Caffeine, Dextromethorphan, Omeprazole, and Midazolam. It indicates changes in area under the curve (AUC) values for these substances in relation to a reference. The values are presented alongside the respective substrates' involvement with specific cytochrome P450 enzymes such as CYP1A2, CYP2D6, CYP2C19, and CYP3A.*

This information presents LS Mean (SE) SKAMP Deportment Scores for two different conditions: Placebo and Lisdexamfetamine Dimesylate. The scores are displayed over a period of time post-dose in hours (0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 7.5, 10, 12, 13). It appears to be a comparison of the effects of these substances on deportment.*

This data table shows the proportion of subjects with relapse/temperature failure over a period of time in a medical study comparing a placebo to Lisdexamfetamine Dimesylate. The percentage of subjects experiencing relapse/temperature failure is plotted against time (in days after randomization) using a line graph.*

This is a chart showing the proportion of subjects with relapse or treatment failure over time (in days after randomization) for both the placebo and Lisdexamfetamine Dimesylate groups. It appears to be a visual representation of the data, with relapse/treatment failure percentages plotted over time.*